phrykt

Eledon Pharmaceuticals, Inc. (ELDN): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ELDN were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Eledon Pharmaceuticals

From the latest filings

Overall: more buying than selling. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ELDN

161 funds and institutions reported ELDN shares worth $186M at the end of Q2 2026, about 62% of the company. The largest holder is Bvf Inc with 8.3%.

Funds and institutions (13F) 62%Everyone else 38%

10 largest owners, by share of the company

Bvf Inc8.3%
BlackRock, Inc.6.8%
Defilade Capital Management, L.P.4.6%
Vanguard Capital Management LLC4.5%
Goldman Sachs Group Inc3.3%
Ensign Peak Advisors, Inc2.8%
Geode Capital Management, LLC2.6%
Catalio Capital Management, LP2.2%
State Street Corp2.1%
Zimmer Partners, LP2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bvf Inc6.29M8.30%$24.8MNo change
BlackRock, Inc.5.12M6.76%$20.2M+17%
Defilade Capital Management, L.P.3.53M4.65%$13.9M-1%
Vanguard Capital Management LLC3.42M4.51%$13.5M+4%
Goldman Sachs Group Inc2.51M3.31%$9.9M+578%
Ensign Peak Advisors, Inc2.10M2.77%$8.3M-15%
Geode Capital Management, LLC1.96M2.58%$7.7M+9%
Catalio Capital Management, LP1.70M2.23%$6.7M+3%
State Street Corp1.62M2.14%$6.4M+40%
Zimmer Partners, LP1.60M2.10%$6.3M-15%
Sphera Funds Management Ltd.1.19M1.57%$4.7M-33%
AWM Investment Company, Inc.1.10M1.45%$4.3MNo change
UBS Group AG1.05M1.38%$4.1M+91%
Kingdon Capital Management, L.l.c.1.04M1.37%$4.1MNo change
Millennium Management LLC979,7121.29%$3.9M–
Bank of America Corp883,0971.16%$3.5M+2%
ADAR1 Capital Management, LLC647,8120.85%$2.6M-34%
22nw, LP636,3640.84%$2.5MNo change
Northern Trust Corp616,3990.81%$2.4M+13%
AQR Capital Management LLC581,0280.77%$2.3M+237%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No ELDN insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ELDN short interest

High short interest. 10.2% of ELDN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 22%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.25M ELDN shares were sold short, 10.2% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 7.5 trading days (days to cover).

Shares short, % of all shares

10.2%May 15Oct 3010.8%

Days to cover

7.5May 15Oct 3011.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.25M10.16%+5%1.10M7.5
Oct 15, 20267.90M9.72%+1%770,15910.2
Sep 30, 20267.85M9.66%-5%888,9378.8
Sep 15, 20268.26M10.16%+7%919,1039.0
Aug 31, 20267.75M9.53%+23%958,3818.1
Aug 14, 20266.29M7.74%+1%915,0836.9
Jul 31, 20266.21M8.19%+13%957,4006.5
Jul 15, 20265.52M7.28%-29%1.43M3.9
Jun 30, 20267.83M10.33%+4%2.43M3.2
Jun 15, 20267.50M9.89%+3%1.01M7.5
May 29, 20267.28M9.60%+7%920,2167.9
May 15, 20266.78M8.94%-10%1.27M5.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Eledon Pharmaceuticals company events

Eledon Pharmaceuticals filed 5 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 13, 2026.

  1. Aug 13, 2026ResultsReleased financial results. Filing
  2. Jun 22, 2026VoteReported shareholder vote results. Filing
  3. May 13, 2026ResultsReleased financial results. Filing
  4. Mar 19, 2026ResultsReleased financial results. Filing
  5. Jan 2, 2026SharesSold new shares outside a public offering. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Eledon Pharmaceuticals financials

Famous investors that hold ELDN

4 of the 50 well-known investors we track reported holding ELDN in their latest 13F filing. The largest position is Israel Englander's, worth $2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026789,861$2M0.0%-19%
Jim Simons · Renaissance TechnologiesQ3 2026556,900$1.4M0.0%+177%
Steve Cohen · Point72 Asset ManagementQ3 202653,247$135K0.0%New
Ken Griffin · Citadel AdvisorsQ3 202632,201$81.5K0.0%-85%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ELDN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A7.0%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A7.0%
Oct 30, 2026Vanguard Capital Management13G/A4.9%
Oct 30, 2026Vanguard Capital Management13G/A4.9%

Questions about Eledon Pharmaceuticals, Inc. (ELDN) stock

Who owns the most ELDN stock?

The largest reported owner of Eledon Pharmaceuticals, Inc. (ELDN) is Bvf Inc, with 8.3% of the company. In total, 161 funds and institutions reported holding ELDN at the end of Q2 2026, together about 62% of the shares. See the largest owners.

Are ELDN insiders buying or selling?

No ELDN insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ELDN?

As of Oct 30, 2026, 8.25M ELDN shares were sold short, 10.2% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 7.5 trading days (days to cover). See the history.

Which famous investors hold ELDN?

4 of the 50 well-known investors we track reported ELDN in their latest 13F filing, including Israel Englander, Jim Simons, Steve Cohen. The largest position is worth $2M. See all holders.

Executive pay

Eledon Pharmaceuticals's chief executive was paid a total of $3.2M for the year ended Dec 31, 2025, down 43% from $5.6M the year before. In the last 12 months, Eledon Pharmaceuticals's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$3.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$1.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.